首页 | 本学科首页   官方微博 | 高级检索  
     

康柏西普联合卵磷脂络合碘治疗视网膜中央静脉阻塞的效果及对视力、VEGF、NO和ET-1水平的影响
引用本文:高建萍. 康柏西普联合卵磷脂络合碘治疗视网膜中央静脉阻塞的效果及对视力、VEGF、NO和ET-1水平的影响[J]. 实用防盲技术, 2021, 0(1): 28-30
作者姓名:高建萍
作者单位:常德市第一人民医院
摘    要:目的探究治疗视网膜中央静脉阻塞(central retinal vein occlusion,CRVO)行玻璃体腔内注射康柏西普联合卵磷脂络合碘的临床疗效,以及对视力、血管内皮生长因子(vascular endothelial growth factor,VEGF)、一氧化氮(nitric oxide,NO)、内皮素-1(endothelin-1,ET-1)的影响。方法选取2017年1月~2019年7月于我院治疗的视网膜中央静脉阻塞患者94例,并随机分为对照组和观察组,每组各47例。对照组行玻璃体腔注射康柏西普眼用注射液,治疗组在对照组治疗的基础上口服卵磷脂络合碘胶囊。比较两组患者临床疗效,疾病相关指标眼压(intraocular pressure,IOP)、最佳矫正视力(Best corrected visual acuity,BCVA)、黄斑中心凹视网膜厚度(central macular thickness,CMT)水平和血清相关因子VEGF、NO、ET-1水平。结果观察组治疗总有效率为95.24%,明显高于对照组的80.95%,差异有统计学意义(P<0.05)。两组治疗后IOP、BCVA、CMT水平与治疗前比较明显降低,差异有统计学意义(P<0.05);观察组治疗后IOP、BCVA、CMT水平明显低于对照组,差异有统计学意义(P<0.05)。两组治疗后VEGF、NO、ET-1水平水平与治疗前比较明显降低,差异有统计学意义(P<0.05)。观察组治疗后VEGF、NO、ET-1水平明显低于对照组,差异有统计学意义(P<0.05)。结论治疗视网膜中央静脉阻塞时,采用玻璃体腔内注射康柏西普联合卵磷脂络合碘临床疗效更优,显著提高患者视力,改善机体细胞因子水平。具有临床上推广应用价值。

关 键 词:康柏西普  卵磷脂络合碘  视网膜中央静脉阻塞  VEGF  NO  ET-1

Effect of intravitreal injection of Conbercept combined with taking Iodizedlecithin orally on central retinal vein occlusion and its effect on visual acuity and the levels of VEGF,NO and ET-1
GAO Jian-ping. Effect of intravitreal injection of Conbercept combined with taking Iodizedlecithin orally on central retinal vein occlusion and its effect on visual acuity and the levels of VEGF,NO and ET-1[J]. Journal of Practical Preventing Blind, 2021, 0(1): 28-30
Authors:GAO Jian-ping
Affiliation:(The First People's Hospital of Changde city,Changde,HUNan 415000)
Abstract:Objective To investigate the clinical efficacy of intravitreal injection of Conbercept combined with taking Iodizedlecithin orally in the treatment of central retinal vein occlusion(CRVO),and the effect on visual acuity,levels of vascular endothelial growth factor(VEGF),nitric oxide(NO)and endothelin-1(ET-1).Methods Ninety-four patients with central retinal vein occlusion treated in our hospital from January 2017 to July 2019 were randomly divided into control group and observation group,with 47 cases in each group.The control group received intravitreal injection of Conbercept only,and the observation group took Iodizedlecithin orally on the basis of the control group.The clinical efficacy,disease-related indicators intraocular pressure(IOP),best corrected visual acuity(BCVA),central macular thickness(CMT)and the levels of serum related factors VEGF,NO,ET-1 of the two groups were compared.Results The total effective rate of the observation group was 95.24%,which was significantly higher than that of the control group(80.95%)(P<0.0).The levels of IOP,BCVA and CMT in the two groups were significantly lower than those before treatment(P<0.05).Compared with the control group,the observation group was significantly lower(P<0.05).The levels of VEGF,NO and ET-1 were significantly lower than those before treatment(P<0.05),and significantly lower in the observation group than those in the control group(P<0.05).Conclusion In the treatment of central retinal vein occlusion,the intravitreal injection of Conbercept combined with taking Iodizedlecithin orally has better clinical efficacy,significantly improve the patient’s vision and cytokine levels.It has the value of popularization and application in clinical practice.
Keywords:Conbercept  Iodizedlecithin  Central retinal vein occlusion  VEGF  NO  ET-1
本文献已被 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号